Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors Harboring ROS1 or NTRK1-3 Rearrangements

NCT05828303 is registered in ClinicalTrials.gov with Turning Point Therapeutics, Inc. as lead sponsor.

NCT NCT05828303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05828303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors Harboring ROS1 or NTRK1-3 Rearrangements
Lead sponsor
Turning Point Therapeutics, Inc.
Phase
Phase 1
Overall status
Withdrawn
Start date
November 15, 2024
Completion date
November 30, 2025
Enrollment
0 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, metastatic solid tumor